Related Experiment Videos
Real-World Evidence Assessment of the Risk of Nonfatal Stroke in Patients Prescribed SGLT2 Inhibitors
Alessandra T Ayers1, Cindy N Ho1, Umesh Masharani2
1Diabetes Technology Society, Burlingame, California, USA.
Aims:
Use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adults with Type 2 diabetes (AwT2D) has recently been associated with decreased stroke risk. In this study, we investigate the impact of SGLT2i on stroke.
Materials And Methods:
We conducted a cohort study using an electronic health record (EHR) representing 66 million patients to examine whether AwT2D have a lower incidence of stroke and/or transient ischemic attack (TIA) if treated with SGLT2i. All analyses were completed utilizing high-dimensional propensity score matching to control for confounders.
Results:
AwT2D treated with SGLT2i compared to other antidiabetic medications, assessed after 1 year, starting 2 weeks after the date of prescription of SGLT2i or other antidiabetic drug, had a significantly lower incidence of any stroke (Odds Ratio (OR): 0.84 with 95% Confidence Interval (CI) 0.79-0.91, p < 0.001), hemorrhagic stroke (OR: 0.72 with 95% CI 0.59-0.88, p < 0.001), ischemic stroke (OR: 0.86 with 95% CI 0.77-0.95, p = 0.005), and TIA (OR: 0.87 with 95% CI 0.80-0.95, p = 0.003).
Conclusion:
Among AwT2D, those treated with SGLT2i had lower incidence of stroke and TIA compared with adults treated with other antidiabetic medications.
